Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.44 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.42 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | AHR | P35869 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | RAF1 | P04049 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382399 | 0.92 | MAPK14 (0.59) | MAPK14SRCBRAFKDRCSNK1A1 | |
| SCHEMBL5385623 | 0.87 | MAPK14 (0.51) | MAPK14CSNK1A1CSNK1DCSNK1EKDM4E | |
| SCHEMBL5385676 | 0.87 | MAPK14 (0.50) | MAPK14KDM4EAHRRAF1CYP1A2 | |
| SCHEMBL5367429 | 0.83 | MAPK14 (0.48) | MAPK14CSNK1DCSNK1EKDM4ENR3C1 | |
| SCHEMBL5384291 | 0.81 | MAPK14 (0.46) | MAPK14KDRSMN1; SMN2AHRADORA2A | |
| SCHEMBL5727609 | 0.81 | MAPK14 (0.60) | MAPK14SRCBRAFKDRCSNK1A1 | |
| SCHEMBL6598145 | 0.81 | MAPK14 (0.63) | MAPK14SRCBRAFKDRCSNK1A1 | |
| SCHEMBL5398429 | 0.81 | MAPK14 (0.63) | MAPK14SRCBRAFKDRCSNK1A1 | |
| SCHEMBL5370357 | 0.80 | MAPK14 (0.46) | MAPK14LMNA | |
| SCHEMBL5388978 | 0.80 | MAPK14 (1.00) | MAPK14SRCBRAFKDRCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4638448-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | Bright Angel Therapeutics Inc. (CA) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024130408-A1 | CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF | BRIGHT ANGEL THERAPEUTICS INC. (CA) | 2024-06-27 | — | — | WO | disclosed |
| US-7223772-B1 | Pyrazolopyridine derivatives as selective cox-2 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-29 | — | — | US | disclosed |
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
| EP-1127058-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2004-09-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| EP-1127058-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-08-29 | — | — | EP | disclosed |
| WO-2000026216-A1 | PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | MAPK14 77/4885SRC 193/4885BRAF 27/4885 |
| US-20050107400-A1 | Use of pyrazolopyridines as therapeutic compounds | QDPR, DPYD, ENTPD5 | MAPK14 1551/4885SRC 3442/4885BRAF 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.